PTC Therapeutics Q1 2024 GAAP EPS $(1.20) Beats $(1.29) Estimate, Sales $210.118M Beat $169.703M Estimate
Portfolio Pulse from Benzinga Newsdesk
PTC Therapeutics (NASDAQ:PTCT) reported Q1 2024 earnings with a GAAP EPS of $(1.20), surpassing the $(1.29) estimate, and sales of $210.118M, exceeding the $169.703M estimate. This represents a 4.66% decrease in sales compared to the same period last year.
April 25, 2024 | 8:39 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
PTC Therapeutics reported better-than-expected Q1 2024 earnings and sales, with a slight decrease in sales compared to last year.
Beating both EPS and sales estimates typically has a positive impact on a company's stock price in the short term. The reported decrease in sales year-over-year is a concern, but the significant beat on both fronts should outweigh the negative aspects, leading to a positive outlook for PTCT's stock in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100